Zobrazeno 1 - 10
of 350
pro vyhledávání: '"Paul F, Schellhammer"'
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 39:514-520
This narrative of the history of the Society of Urologic Oncology (SUO) presents the story of the founding and development of this organization and the creation and establishment of its initiatives and programs. It includes a description of how "Urol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8211d8ee2a9b2a2cdb82cab2c807c761
https://doi.org/10.1016/j.urolonc.2020.12.018
https://doi.org/10.1016/j.urolonc.2020.12.018
Publikováno v:
Clinical Genitourinary Cancer. 18:416-422
Background Numerous globally approved castration-resistant prostate cancer (CRPC) therapies are available. Enzalutamide and radium 223 (Ra 223) are approved for survival prolongation and ability to delay radiographic progression. Both have markedly d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4b40f67766f06af5556385c3a716ee7
https://doi.org/10.1016/j.clgc.2020.02.015
https://doi.org/10.1016/j.clgc.2020.02.015
Autor:
Ronald F. Tutrone, Andrew J. Armstrong, Oliver Sartor, Paul F. Schellhammer, Matthew Harmon, Stephen J. Freedland, David I. Quinn, Neal D. Shore, Arif Hussain, David G. McLeod, Philip W. Kantoff, Nicholas J. Vogelzang, Matthew R. Cooperberg, Nadeem A. Sheikh, Chiledum Ahaghotu, Eric J. Small, Celestia S. Higano, David F. Penson, Elisabeth I. Heath, Nancy N. Chang, Christopher Michael Pieczonka, Bruce Brown
Publikováno v:
Prostate Cancer and Prostatic Diseases
Prostate cancer and prostatic diseases, vol 23, iss 3
Prostate cancer and prostatic diseases, vol 23, iss 3
Purpose African Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences in overall survival (OS) between African American and Caucasian men receiving sipuleucel-T.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df74513fcaa9682c5e2bb9c293892617
http://europepmc.org/articles/PMC7423504
http://europepmc.org/articles/PMC7423504
Autor:
Paul F. Schellhammer, Richard Moriarty
Publikováno v:
Cancer Screening ISBN: 9780429179587
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24e6e4fcdeff69dba78293610891bae3
https://doi.org/10.1201/9780429179587-11
https://doi.org/10.1201/9780429179587-11
Autor:
Donald F. Lynch, Paul F. Schellhammer
Publikováno v:
The Scientific World Journal, Vol 4, Pp 179-191 (2004)
Externí odkaz:
https://doaj.org/article/784706ad03944140a721c771b9615f03
Autor:
Celestia S. Higano, David G. McLeod, Neal D. Shore, Louis Denis, Mario A. Eisenberger, E. David Crawford, Fernand Labrie, Paul F. Schellhammer, Judd W. Moul, Peter Iversen
Publikováno v:
Journal of Urology. 200:956-966
Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of prostate cancer.We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d739055bbdfb107c83e6b50ace398fd
https://doi.org/10.1016/j.juro.2018.04.083
https://doi.org/10.1016/j.juro.2018.04.083
Autor:
Paul F. Schellhammer, David I. Quinn, Ronald F. Tutrone, Arif Hussain, Celestia S. Higano, David G. McLeod, Christopher Michael Pieczonka, Neal D. Shore, Nancy N. Chang, Elisabeth I. Heath, Matthew Harmon, Chiledum Ahaghotu, Stephen J. Freedland, Philip W. Kantoff, Andrew J. Armstrong, Oliver Sartor, David F. Penson, Nicholas J. Vogelzang, Matthew R. Cooperberg
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 29:D084-D084
BACKGROUND: Prostate cancer risk and mortality are higher in AAs versus CAUs. Post-hoc analyses of pooled Phase 3 data (n = 737) suggested substantial OS benefit for AA men receiving sipuleucel-T (n=33) vs placebo (n = 10) (McLeod 2012). Compared wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e303a061928a288d0735e8b94174601
https://doi.org/10.1158/1538-7755.disp19-d084
https://doi.org/10.1158/1538-7755.disp19-d084
Publikováno v:
Journal of Urology. 199
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2e5f3fc0034880cc3493157b3eb0fa2
https://doi.org/10.1016/j.juro.2018.02.2911
https://doi.org/10.1016/j.juro.2018.02.2911
Autor:
Paul H. Lange, James E. Montie, Erik Wibowo, Richard J. Wassersug, Paul F. Schellhammer, S. Larry Goldenberg
Publikováno v:
Trends in Urology & Men's Health. 6:31-34
PSA screening for prostate cancer is a controversial issue around the world. In this article the authors describe the situation in North America where screening is not being advised. They argue that patients should be tested and that men will adapt a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90f0f404f3c56f41a74ce14bf665815d
https://doi.org/10.1002/tre.484
https://doi.org/10.1002/tre.484
Autor:
Paul F. Schellhammer
Publikováno v:
Robotics in Genitourinary Surgery ISBN: 9783319206448
A urologist’s personal experience with multiple surgical, hormonal, and radio/immunotherapeutic options for the treatment of advancing prostate cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db8177a814f0ae48e18c4125ae395f9
https://doi.org/10.1007/978-3-319-20645-5_11
https://doi.org/10.1007/978-3-319-20645-5_11